Patents by Inventor Tim Carlton

Tim Carlton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10772839
    Abstract: There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: September 15, 2020
    Assignee: VHsquared Limited
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Gary Whale, John Wahlich, Mike Frodsham
  • Patent number: 10633438
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to TNF-alpha, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: April 28, 2020
    Assignee: VHsquared Limited
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Keith Ray
  • Publication number: 20190307891
    Abstract: There is provided inter alia a composition comprising a TNF-alpha binding polypeptide and an IL-6R binding polypeptide.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 10, 2019
    Inventors: SCOTT CROWE, KEVIN ROBERTS, TIM CARLTON, LUANA MAGGOIRE, MARION CUBITT, MIKE WEST, KEITH RAY
  • Publication number: 20190092855
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Application
    Filed: July 20, 2018
    Publication date: March 28, 2019
    Inventors: Scott Crowe, Tim Carlton, Marion Cubitt, Kevin Roberts, Luana Maggiore, Mike West, Keith Ray
  • Publication number: 20190008778
    Abstract: There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.
    Type: Application
    Filed: September 25, 2018
    Publication date: January 10, 2019
    Applicant: VHSQUARED LIMITED
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Gary Whale, John Wahlich, Mike Frodsham
  • Publication number: 20180100009
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to Clostridium difficile toxin A.
    Type: Application
    Filed: September 27, 2017
    Publication date: April 12, 2018
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Nika Strokappe, Theo Verrips
  • Publication number: 20180100008
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to Clostridium difficile toxin B.
    Type: Application
    Filed: September 27, 2017
    Publication date: April 12, 2018
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Nika Strokappe, Theo Verrips
  • Publication number: 20180009881
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1-CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue; wherein the polypeptide has increased intestinal stability relative to a corresponding polypeptide not having said histidine substitutions.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 11, 2018
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton
  • Publication number: 20170002069
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to TNF-alpha, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Application
    Filed: September 22, 2016
    Publication date: January 5, 2017
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Keith Ray